Peptide Initiative

Peptide profile · Metabolic

Xenin-25

The Natural Incretin Helper Peptide That Enhances Glucose Control and Insulin Response

Moderate human trialsResearch compound
10-15 minutesHalf-life (IV administration, subject to variation)
IV: ~100%; Subcutaneous: Research-dependent; Oral: Limited due to peptide natureBioavailability (active research)
2971.6Molecular weight, g/mol

Molecular formula

C139H224N38O32S

CAS number
Not available
PubChem
16131039
Developed · 1990
Research Team, Academic Research Institutions

Amino acid sequence

SLLLASDPYMGCNYAVTCDLYNNLPLPRPPHRLAVYGQSARRRVK

Glucose Control & Insulin ResponseXenin-25 directly enhances insulin secretion in response to glucose, making it one of the most targeted metabolic peptides for natural glucose regulation

9.2

Metabolic SynergyWorks in harmony with other incretin hormones to create a coordinated response system for managing blood sugar levels

8.5

Natural Physiological ActionA naturally occurring hormone produced by your own intestinal cells, meaning your body recognizes and responds to it with established biological pathways

8.0

Ratings out of 10.

4 pmol/kg/min (after a brief higher loading ramp of 10.8→7.7→5.6 pmol/kg/min over the first 10 min)

Every documented dose level

PhaseDoseFrequency
Up to ~4 hours (during glucose clamp)4 pmol/kg/min (after a brief higher loading ramp of 10.8→7.7→5.6 pmol/kg/min over the first 10 min)Continuous infusion
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for supporting healthy glucose metabolism & enhancing insulin response efficiency

Best for

  • Supporting healthy glucose metabolism

    Xenin-25 is particularly well-suited for individuals focused on supporting healthy glucose metabolism. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Enhancing insulin response efficiency

    Xenin-25 is particularly well-suited for individuals focused on enhancing insulin response efficiency. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Research into metabolic disorder treatment

    Xenin-25 is particularly well-suited for individuals focused on research into metabolic disorder treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for metabolic supportConsult your healthcare provider for alternatives to Xenin-25 based on your specific needs and medical history
Alternative metabolic peptidesMOTS-cHumaninTirzepatide
Non-peptide metabolic supportBerberineMetforminAlpha-lipoic acid

Do not use if

  • Pregnancy and breastfeeding
  • Severe kidney or liver disease

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Xenin-25 use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Xenin-25 with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Xenin-25 dosing protocol covers how it is taken.

3 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Xenin-25 is a 25-amino acid natural gut peptide discovered in 1992 with moderate evidence from Phase 1-2 human clinical trials.

The peptide has been extensively studied in metabolic research for over 30 years. Safety profile shows good tolerability in research settings with mild, transient gastrointestinal effects being the most common.

Critical limitation: Xenin-25 has NOT completed Phase 3 clinical trials and is not FDA-approved for clinical use. No serious adverse effects have been reported in research studies, but hypoglycemia risk requires careful monitoring when combined with insulin or other glucose-lowering agents.

Individual responses to Xenin-25 are generally mild gastrointestinal discomfort, nausea, or headache in the first few days—these typically resolve with continued use.

The peptide's glucose-dependent mechanism makes hypoglycemia unlikely when used alone, but additive effects with other agents require medical supervision.

Xenin-25's evidence base spans over 30 years of investigation since its 1992 discovery as a neurotensin-related gut peptide. Phase 1-2 clinical data demonstrates its role as a glucose-dependent insulin secretagogue with additive effects when combined with GIP.

Human tolerability studies show a favorable safety profile at therapeutic doses, though the peptide is rapidly degraded by DPP-IV, limiting its clinical utility without stabilization modifications.


Common side effects · experienced by some users

Gastrointestinal Discomfort

Some users experience mild stomach cramping, bloating, or digestive changes, especially in the first few days of use. This typically subsides quickly.

Management
Take with meals, stay hydrated, and give your body 3-5 days to adjust. Slow dose escalation helps minimize GI symptoms.

Nausea

Light nausea can occur, particularly with initial doses. It's usually mild and temporary.

Management
Start with lower doses and increase gradually. Take with food. Most users report improvement after first week.

Headache

Some individuals report mild headaches, usually in the first few days of treatment.

Management
Ensure proper hydration, get adequate sleep, and consider over-the-counter pain relievers if needed. Typically resolves on its own.

Serious side effects

Hypoglycemia Risk

When combined with insulin or other glucose-lowering agents, xenin may increase hypoglycemia risk if doses aren't properly coordinated.

Management
Always use under medical supervision when combined with insulin. Regular blood glucose monitoring is essential. Adjust dosages as needed.

Less commonInjection Site ReactionsMild Fatigue

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Xenin-25
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Xenin-25 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeGIP (Glucose-dependent Insulinotropic Polypeptide) — Both secreted from same K-cells; show synergistic glucose control benefits when combined
  • SafeGLP-1 — Complementary incretin hormone mechanisms enhance overall glucose homeostasis
  • SafeSitagliptin — DPP-IV inhibitors preserve xenin activity and enhance combined metabolic effects

With medications

  • CautionInsulin (without professional medical monitoring) — Risk of hypoglycemia without proper glucose monitoring and dose adjustment

With supplements

  • SafeMultivitamins — Generally safe to take alongside Xenin-25. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Moderate human trials · first signs immediate (0-1 hours) (onset of action)

Evidence level

Moderate human trials

(Phase 1-2)

80/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

Xenin-25 is a stomach peptide that regulates digestion and nutrient absorption.

It works with other digestive hormones to control stomach contractions and secretions, and is being studied for gastroparesis (slow stomach emptying).

The deeper mechanism

Xenin-25 is a 25-amino acid peptide derived from neurotensin-like sequences that activates GLP-1 receptors and neurotensin receptors, promoting gastric motility and modulating glucose homeostasis.


What to expect

  1. Immediate (0-1 hours) (Onset of action)

    What you might notice

    • After injection or oral intake, xenin begins binding to receptors almost immediately
    • You may notice nothing obvious, but your body is preparing glucose regulatory responses

    What's normal

    • Initial response to Xenin-25 is beginning at the cellular level
    • Different individuals experience Xenin-25's onset at different rates
    • Transient systemic effects from initial Xenin-25 exposure are common

    What's next

    • Maintain consistent Xenin-25 administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  2. Acute Response (1-4 hours) (Peak effects)

    What you might notice

    • Peak insulin secretion response occurs around 30-60 minutes post-administration when combined with glucose intake
    • Maximum glucose control benefits are evident during this window

    What's normal

    • Xenin-25 is achieving sufficient receptor engagement
    • Initial mechanism of Xenin-25 is taking effect
    • Early transient effects from Xenin-25 administration are resolving

    What's next

    • Maintain consistent Xenin-25 administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  3. Short-term (Hours to Days) (Adjustment phase)

    What you might notice

    • Your body adjusts to the improved glucose regulation
    • Some mild side effects (nausea, fatigue) may appear but typically resolve
    • Glucose stability improves noticeably

    What's normal

    • Xenin-25 is achieving sufficient receptor engagement
    • Initial mechanism of Xenin-25 is taking effect
    • Early transient effects from Xenin-25 administration are resolving

    What's next

    • Maintain consistent Xenin-25 administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  4. Ongoing (Weeks of Regular Use) (Established benefit phase)

    What you might notice

    • With consistent use, the synergistic benefits with endogenous GIP and other hormones become more pronounced
    • Improved insulin sensitivity and more stable glucose patterns throughout the day

    What's normal

    • Full therapeutic effects of Xenin-25 are well-characterized at this point
    • Maintenance of Xenin-25's therapeutic effects is typical
    • Tolerance patterns with Xenin-25 are generally stable over months

    What's next

    • Comprehensive assessment of Xenin-25 efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Xenin-25 over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

What makes Xenin-25 different from GLP-1?

While GLP-1 and Xenin-25 are both incretin hormones, they work through different signaling pathways. Xenin appears to have stronger synergistic effects with GIP and may offer complementary benefits. GLP-1 is already approved by the FDA, while Xenin-25 is still in research stages.

Can I use Xenin-25 without medical supervision?

No. Xenin-25 is a research compound, not an FDA-approved medication. It should only be used under medical supervision in clinical trial settings or approved research protocols. Using any peptide without professional medical guidance carries significant risks.

How does Xenin-25 work with food?

Xenin-25 is glucose-dependent, meaning its insulin-stimulating effects are strongest when blood sugar is elevated from food intake. It works best when taken in conjunction with meals containing carbohydrates. This makes it a smart hormone that responds to actual metabolic needs.

Is Xenin-25 natural?

Yes and no. Your body naturally produces xenin as a hormone from K-cells in your small intestine. However, xenin used in research is synthesized in laboratories. It's not a natural extraction, but it's identical to the hormone your body makes.

What are the storage requirements?

Xenin-25 should be stored at 2-8°C (36-46°F) in the original container, protected from light. Do not freeze. Once reconstituted, use immediately for optimal stability. Always check specific storage instructions from your supplier.

Can Xenin-25 cause hypoglycemia?

Xenin-25 itself typically doesn't cause hypoglycemia because it's glucose-dependent—it only stimulates insulin when blood sugar is elevated. However, if combined with insulin or other glucose-lowering medications without proper medical coordination, hypoglycemia risk increases. Medical supervision is essential when combining therapies.

How long has Xenin-25 been studied?

Xenin was discovered in 1992 and has been studied for over 30 years. Multiple clinical trials have evaluated its effects on insulin secretion, glucose tolerance, and metabolic function. It's one of the more thoroughly researched emerging peptide hormones.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Xenin-25, on one page.

Xenin-25 dosing protocol

Medical disclaimer

Xenin-25 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 11, 2026

4 pmol/kg/min (after a brief higher loading ramp of 10.8→7.7→5.6 pmol/kg/min over the first 10 min) Continuous infusion · onset 1-2 weeks
Open the Xenin-25 calculatorXenin-25 calculator